US biotech major Celgene’s (Nasdaq: CELG) recent announcement of the acquisition of Juno Therapeutics has put the company in a good position to be a frontrunner in the chimeric antigen receptor- T cell (CAR-T) space.
Celgene stands to benefit from Juno’s expertise and ongoing work into addressing concerns surrounding CAR-T, according to data and analytics company GlobalData.
In January 2018, Celgene announced a $9 billion cash buyout of the remaining 90% stake in Juno Therapeutics that it does not already own. This news signals a significant, albeit risky, push for Celgene in the cellular immunotherapies space, where the company sees Juno’s lead CAR-T candidate, JCAR017, bringing in $3 billion in sales, with a potential US Food and Drug Administration approval next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze